Latest Strategy News

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Clara Resources has completed acquisition of the Mareeba Gold Project, initiating modern exploration and refocusing its portfolio on Queensland gold assets while securing fresh capital and leadership changes.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

Marquee Resources has significantly increased its Mt Clement inferred antimony resource and is advancing drilling and strategic partnerships to develop its flagship project.

Beonic Limited’s Q3 FY26 results highlight a tripling of EBITDA margin to 15.8%, driven by operational leverage and gross margin expansion, while the Moroccan Airports rollout stays on track for full delivery by June 2026.

Future Metals has trimmed pre-production capital for its Panton PGM Project by approximately A$74 million through an independent engineering assessment of the Savannah processing facility. Further savings are possible by shifting crushing and ore sorting to Panton, while rising platinum group metal prices bolster project economics.

Pointerra Limited delivered a 214% jump in Q3 FY26 customer receipts to A$2.2 million, driven by milestone invoicing and new Tier 1 utility contracts, edging closer to operating cashflow breakeven.

Cyprium Metals has made substantial progress on its Nifty Copper Complex restart, targeting copper cathode production by September 2026 while securing A$41 million to fuel exploration and growth.

Encounter Resources (ASX:ENR) has reported a major 83% increase in the Green deposit’s inferred niobium resource at its Aileron project, lifting the combined inferred mineral resource by 54%. Meanwhile, copper-gold drilling advances in the Paterson Province as the company targets Havieron-style systems.

Adavale Resources reports strong assays from initial drillholes at London-Victoria, revealing high-grade northern lodes and broad southern mineralisation that underpin resource growth potential.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Pivotal Metals has kicked off drilling at its Belleterre projects and reported promising metallurgical testwork at Horden Lake, supporting an upcoming resource update and scoping study.